Actively Recruiting
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
Led by University of Chicago · Updated on 2025-11-10
280
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
CONDITIONS
Official Title
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Ability to provide consent
- Positive Covid-19 saliva test or positive home rapid antigen test confirmed by saliva sample
- Ability to follow study instructions and procedures
- Willingness to provide saliva samples every other day for 10 days and report symptoms
- Vaccinated against Covid-19
- Having no symptoms or only mild symptoms of Covid-19
- Ability to provide consent (close contacts)
- Ability to follow study instructions and report side effects (close contacts)
- Ability to provide saliva samples throughout the study (close contacts)
- Vaccinated against Covid-19 (close contacts)
You will not qualify if you...
- Pregnant, breastfeeding, or planning pregnancy
- Known allergy or hypersensitivity to intranasal azelastine
- Use of other Covid-19 treatments like steroids, plasma, or antibodies
- Use of intranasal corticosteroids, immunomodulators, or medications that affect Astepro
- Previous Covid-19 infection more than 5 and less than 30 days before enrollment
- Participation in another research study within the last 30 days
- Allergic reaction to olopatadine, diphenhydramine, or hydroxyzine
- Not vaccinated against Covid-19
- Moderate to severe Covid-19 symptoms or urgent/emergency signs such as shortness of breath or chest pain
- Prior Covid infection less than 30 days or more than 5 days before enrollment (close contacts)
- Positive Covid-19 test before the primary cohort subject's positive test (close contacts)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
B
Brandon Baird
CONTACT
S
Shalitha Johnson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here